From: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years’ experience
Survival
Primary OC
n = 11
Recurrent OC
n = 30
Platinum Sens*
n = 13
Platinum Res**
n = 17
Progression-free (months)
30.0
6.7
30.8
6.5
Median overall (months)
67.0
18.1
31.5
12.8
5-year (%)
27.0
3.0